{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell&page=17",
    "query": {
      "condition": "Hematopoietic Stem Cell",
      "page": 17
    },
    "page_size": 10
  },
  "pagination": {
    "page": 17,
    "page_size": 10,
    "total_count": 2616,
    "total_pages": 262,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell&page=18&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell&page=16&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-25T10:20:10.511Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02860039",
      "title": "High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematopoietic Cell Transplantation Recipient",
        "Malignant Neoplasm",
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Trivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Quadrivalent Influenza Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 170,
      "start_date": "2016-09",
      "completion_date": "2024-09",
      "has_results": true,
      "last_update_posted_date": "2024-10-22",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02860039"
    },
    {
      "nct_id": "NCT00252057",
      "title": "Testing the Re-Engineered Hospital Discharge",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "All"
      ],
      "interventions": [
        {
          "name": "Re-Engineered Hospital Discharge",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Boston University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 749,
      "start_date": "2005-12",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2017-03-28",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00252057"
    },
    {
      "nct_id": "NCT06904066",
      "title": "Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Malignancy, Hematologic",
        "Neoplasms, Hematologic",
        "Neoplasms, Hematopoietic",
        "Blood Cancer",
        "Hematological Neoplasms",
        "Hematopoietic Malignancies",
        "Dysmyelopoietic Syndromes",
        "Hematopoetic Myelodysplasia",
        "Myeloid Leukemia, Acute",
        "Nonlymphoblastic Leukemia, Acute",
        "Leukemia, Lymphocytic, Acute"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Individual Patient TCR-Transduced PBL",
          "type": "BIOLOGICAL"
        },
        {
          "name": "TruSight Oncology (TSO) 500",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "DEVICE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 86,
      "start_date": "2026-10-28",
      "completion_date": "2029-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-23",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06904066"
    },
    {
      "nct_id": "NCT01420172",
      "title": "Pulmonary Disease in Patients Undergoing Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Post Hematopoietic Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "Data Collection",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Karen Wood",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2011-08",
      "completion_date": "2016-07-08",
      "has_results": false,
      "last_update_posted_date": "2017-02-27",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01420172"
    },
    {
      "nct_id": "NCT00004105",
      "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Lymphoma",
        "Sarcoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "estramustine phosphate sodium",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "vinorelbine ditartrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "1998-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-03-28",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004105"
    },
    {
      "nct_id": "NCT00664677",
      "title": "Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemias",
        "Acute Myeloid Leukemia (AML)",
        "Acute Lymphocytic Leukemia (ALL)",
        "Adult T Cell Leukemia (ATL)",
        "Chronic Myeloid Leukemia (CML-BP)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Myelodysplastic Syndrome (MDS)",
        "Chronic Myelomonocytic Leukemia (CMML)"
      ],
      "interventions": [
        {
          "name": "Terameprocol (EM-1421)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Erimos Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-08",
      "completion_date": "2009-06",
      "has_results": false,
      "last_update_posted_date": "2016-02-23",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00664677"
    },
    {
      "nct_id": "NCT03699475",
      "title": "Study of Haplo-HSCT + Rivogenlecleucel vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "rivogenlecleucel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "rimiducid",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "haplo-HSCT",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Bellicum Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "12 Years to 70 Years"
      },
      "enrollment_count": 1,
      "start_date": "2018-12-27",
      "completion_date": "2019-07-23",
      "has_results": true,
      "last_update_posted_date": "2023-09-29",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 2,
      "location_summary": "Nashville, Tennessee • San Antonio, Texas",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03699475"
    },
    {
      "nct_id": "NCT04339101",
      "title": "Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Leukemia",
        "Hematologic and Lymphocytic Disorder",
        "Myelodysplastic Syndrome",
        "Primary Myelofibrosis",
        "Secondary Myelofibrosis"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Itacitinib Adipate",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 59,
      "start_date": "2020-11-11",
      "completion_date": "2025-10-09",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04339101"
    },
    {
      "nct_id": "NCT00061945",
      "title": "Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Undifferentiated Leukemia",
        "B-cell Adult Acute Lymphoblastic Leukemia",
        "B-cell Childhood Acute Lymphoblastic Leukemia",
        "L1 Adult Acute Lymphoblastic Leukemia",
        "L1 Childhood Acute Lymphoblastic Leukemia",
        "L2 Adult Acute Lymphoblastic Leukemia",
        "L2 Childhood Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia",
        "Philadelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia",
        "T-cell Adult Acute Lymphoblastic Leukemia",
        "T-cell Childhood Acute Lymphoblastic Leukemia",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Childhood Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "allopurinol",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "asparaginase",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "trimethoprim-sulfamethoxazole",
          "type": "DRUG"
        },
        {
          "name": "mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "alemtuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "acyclovir",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 302,
      "start_date": "2003-06",
      "completion_date": "2012-10",
      "has_results": true,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00061945"
    },
    {
      "nct_id": "NCT00114257",
      "title": "Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms"
      ],
      "interventions": [
        {
          "name": "decitabine",
          "type": "DRUG"
        },
        {
          "name": "romidepsin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2005-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-10-25T10:20:10.511Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00114257"
    }
  ]
}